Syniad Innovations Portfolio Company, Gemina Labs, Appoints Stifel as Financial Advisor

Vancouver, British Columbia – November 6, 2023, Syniad Innovations Inc. (“Syniad”) is pleased to announce that one of its portfolio companies, Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7), a diagnostics technology company, has appointed the global investment bank Stifel as its sole and exclusive financial advisor to the Company, as it considers strategic licensing and partnership opportunities for its breakthrough diagnostics technology. Gemina is targeting a series of significant multi-year licensing deals or partnerships with companies in the life sciences and medical device sectors to enable the delivery of next-generation diagnostics with its unique, validated platform chemistry technology. One of the Company’s technologies, the Gemina Bridge, is a seminal development in the advancement of lateral flow assays (“LFA’s”) and has been evidenced to significantly reduce the amount of antibody required in diagnostic tests while retaining or enhancing test performance. This technology promises to deliver over 75% reduction in antibody requirements to one of the most cost-intensive areas of LFA production and beyond. Integration of this technology inside partner products offers a compelling commercial opportunity for Gemina to engage with industry leaders to help deliver better diagnostics for patients and consumers.  Brian Firth, CEO of Gemina Labs, commented, “We are very excited to be working with Stifel, who brings a huge amount of licensing experience across life sciences, as we look to broaden our licensing partnerships across the full spectrum of Point of Care Diagnostics. Our work with Stifel will ensure the maximum access possible to our breakthrough technologies whilst we focus on our core products.”

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry technology platform that powers next generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technologies drive testing platforms that are fast, affordable, accurate, and easily self-administered. Our own product pipeline includes platforms for the rapid testing of COVID-19, influenza, tuberculosis, and other viruses. Additional information on the Company can be found at www.geminalabs.com.

About Syniad Innovations:

Syniad Innovations is at the forefront of commercializing ground-breaking scientific advancements that positively impact humanity. With a focus on rapid innovation and development, Syniad Innovations is dedicated to addressing the complex threats faced by society today while also exploring opportunities to enhance deterrence and effective defence mechanisms for our armed forces.